Orifarm, officially known as Orifarm Group, is a prominent player in the pharmaceutical industry, headquartered in Denmark (DK). Founded in 1994, the company has established itself as a leader in the development, production, and distribution of generic medicines and parallel imports, primarily serving the European market. With a strong focus on quality and accessibility, Orifarm offers a diverse portfolio of products, including prescription medications and over-the-counter solutions. Their commitment to innovation and sustainability sets them apart in a competitive landscape. Over the years, Orifarm has achieved significant milestones, including expanding its operational reach across multiple European countries. The company is recognised for its dedication to improving patient access to essential medicines, solidifying its position as a trusted partner in the healthcare sector.
How does Orifarm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Orifarm's score of 71 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Orifarm Group A/S reported total carbon emissions of approximately 3,178,000 kg CO2e for Scope 1 and about 7,300,000 kg CO2e for Scope 2 (market-based). This reflects a decrease from 2023, where emissions were about 4,420,000 kg CO2e for Scope 1 and approximately 7,529,000 kg CO2e for Scope 2 (market-based). The company has set ambitious targets to reduce its carbon footprint, aiming for a 30% reduction in both Scope 1 and Scope 2 emissions by 2025, using 2020 as the baseline year. Additionally, Orifarm has committed to long-term reductions, targeting a 54.6% decrease in absolute Scope 1 and 2 emissions by 2033 from a 2023 baseline. For Scope 3 emissions, the company aims for a 32.5% reduction within the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and are designed to support global efforts to limit warming to 1.5°C. Orifarm's emissions data is cascaded from its parent company, Orifarm Group A/S, reflecting its commitment to transparency and accountability in climate action. The company is also focused on achieving net-zero emissions by 2050, with a commitment to exponential reductions in absolute emissions over the coming decades.
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 732,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 
| Scope 2 | 575,000 | 000,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 
| Scope 3 | - | - | - | - | - | - | - | 
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Orifarm has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
